Less than two months after an accelerated approval from the FDA, a drug combination featuring Pfizer’s Braftovi has turned in ...

Drug major Pfizer Inc. (PFE) announced Monday positive topline results from the progression-free survival or PFS analysis of the ...

Pfizer's Braftovi combination showed significant survival benefits in a Phase 3 study for BRAF V600E-mutant metastatic ...

The U.S. State Department said on Saturday that the President's Emergency Plan for AIDS Relief (PEPFAR) — the world's leading ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

Merck KGaA and Pfizer have got the fourth checkpoint inhibitor to market after the US regulator approved their avelumab for a rare form of skin cancer. The FDA’s approval of avelumab ...

It's the second drug in the TFPI class to be approved by the FDA after Pfizer's once-weekly Hympavzi (marstacimab), cleared in October for haemophilia A and B without inhibitors, and has also been ...

NEW YORK, NY, USA I 03, 2025 I Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of ...

The CEO said last month that the drugmaker had cut costs, revamped its sales operation, and made other big fixes.

CEO Albert Bourla says Pfizer has met the strategic goals it had set for itself in 2024, and that it was ‘executing transformative changes.’ ...

Last fall, the drug picked up an FDA nod in patients with HR+/HER2- early breast cancer based on the NATALEE study results. Vaccine specialist Valneva has picked up an approval from the MHRA ...

President Donald Trump's steep tariffs on Canada, Mexico and China could worsen exist­ing drug short­ages in the U.S. and ...